(Q41474108)

1 October 2017

1 reference

title

Is screening for prostate cancer the current gold standard?--"no". (English)

1 reference

1 October 2017

Kramer BS

1

1 reference

1 October 2017

Gohagan JK

series ordinal

2

1 reference

1 October 2017

Prorok PC

series ordinal

3

1 reference

1 October 2017

publication date

1 March 1997

1 reference

European Journal of Cancer

1 October 2017

published in

1 reference

1 October 2017

volume

33

1 reference

1 October 2017

issue

3

1 reference

1 October 2017

page(s)

348-353

1 reference

Rise in prostatic cancer incidence associated with increased use of transurethral resection

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

The role of increasing detection in the rising incidence of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Prostate-specific antigen as predictor of prostate cancer in black men and white men.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Case-control study of screening for prostatic cancer by digital rectal examinations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Disease-specific survival following routine prostate cancer screening by digital rectal examination.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Intermediate determinants of mortality in the evaluation of screening

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Analysis of interval breast carcinomas in a randomized screening trial in Stockholm

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Incidence of and treatment for ductal carcinoma in situ of the breast.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Deferred treatment of low grade stage T3 prostate cancer without distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Changes in prostate cancer incidence and treatment in USA

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

PSA screening: a public health dilemma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Prostate cancer--look to Denmark?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Follow-up prostate cancer treatments after radical prostatectomy: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

A critique of the decision analysis for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Prostate cancer screening: what we know and what we need to know.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Patient-re ported complications and follow-up treatment after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Sequelae of radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Quality-of-life outcomes in men treated for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2989004-1

7 January 2021

10.1016/S0959-8049(97)89004-1

Identifiers

DOI

1 reference

1 October 2017

1 reference